Synopulse
The Pulse
Synopulse’s weekly biopharma briefing – deals, approvals, readouts and access, across every therapy area.
WEEKLY
6 – 12 July 2026
Wk 28 · 2026
6 – 12 July 2026
Wk 28 · 2026
The big events this week
Deal
Vertex acquires Crinetics for $10 billion
The week’s largest transaction – an all-cash move that pushes Vertex decisively into rare endocrine disease.
Read in CardioMeta →
Approval
FDA approves Keytruda + Padcev for bladder cancer
Merck’s flagship IO-plus-ADC combination extends into earlier-stage, peri-operative bladder cancer.
Read in Onco+Immuno →
Clinical
Oral GLP-1 posts positive Phase 3 in obesity
Kailera and Hengrui’s oral small-molecule GLP-1 advances the durability-and-convenience race.
Read in CardioMeta →
Conference
Leqembi subcutaneous data land at AAIC 2026
Home-administration Alzheimer’s dosing could remove a major access barrier to anti-amyloid therapy.
Read in Neurology →
Deal signals
Vertex Pharmaceuticals ← Crinetics Pharmaceuticals
$10.0B$10.0B upfront
Vertex’s biggest move beyond CF – an all-cash buy of Crinetics’ endocrine franchise (acromegaly, Cushing’s), diversifying into rare endocrine disease.
Novartis ← Myricx Bio
$1.5B$1.1B upfront
A high-upfront bet on next-generation ADC payloads (NMT inhibitors) – Novartis doubling down on antibody-drug conjugates.
AstraZeneca ← Sino Biopharmaceutical (Chia Tai Tianqing)
$1.9B$200M upfront
Another China-to-West licensing deal – AstraZeneca reaching into Chinese innovation, the year’s defining cross-border pattern.
Tarsus Pharmaceuticals ← iRenix Medical
$565M$75M upfront
Tarsus expands beyond its eyelid-disease franchise into a broader ophthalmology pipeline.
Genentech (Roche) ← Astex Pharmaceuticals (Otsuka)
$490M$25M upfront
A milestone-heavy cancer discovery deal – low upfront, optionality on an early program.
Also: EQT ← Corza Medical biosurgery business (Business unit purchase) · Praxis Precision ← Remagine Labs (Dev & commercial license) · LG Chem ← OTR Therapeutics (Shanghai) (Dev & commercial license) · Samsung Bioepis ← Proteina (Option to license) · Scipher Medicine ← Chemomab Therapeutics (Reverse merger)
By therapy area
Orphan & rare · Tech & AI
Orphan & rare
ClinicalIonis completes enrollment in the pivotal cohort of the Phase 3 REVEAL study of obudanersen in Angelman syndrome, advancing an antisense therapy in a severe genetic disorder.
ApprovalOctapharma won expanded FDA approval of Wilate for von Willebrand disease prophylaxis in children under 6.
RegulatoryAlterity’s FDA end-of-Phase-2 minutes confirmed a registrational pathway for ATH434 in multiple system atrophy.
RegulatorySaol Therapeutics resubmitted its NDA for SL1009 in pyruvate dehydrogenase complex deficiency, an ultra-rare disease.
ClinicalMighty Therapeutics dosed the first patient in a Phase 4 confirmatory study of elamipretide in Barth syndrome.
Tech & AI
ApprovalFDA cleared CliniComp’s PACS viewer mIMPS, unifying diagnostic imaging, EHR and native AI in a single platform.
AIA bio-native AI company moved to patent the data layer beneath foundation models, staking IP as AI models commoditize.
AIMindbeam AI used generative AI to design novel pain therapeutics with improved predicted liver safety.
AIKythera Labs expanded its Databricks partnership, launching a Clinical Semantic Bridge on the marketplace.
Conference readout
AAIC 2026
Leqembi subcutaneous autoinjector data support efficacy and safety similar to IV in early Alzheimer’s
Eisai/Biogen — home administration could remove a key access barrier to anti-amyloid therapy.
AAIC 2026
Denali gives the opening plenary on delivering biologics across the blood-brain barrier
spotlighting brain-penetrant delivery as a platform theme.
ISTH 2026
Novo Nordisk’s denecimig (Mim8) shows positive long-term Phase 3 data in hemophilia A
FRONTIER extension supports durable efficacy and safety.
ISTH 2026
Hemab presents HMB-002 data in von Willebrand disease and introduces HMB-003
expanding a rare-bleeding-disorder pipeline.
Neurology / CNS
Therapy area
Neurology & CNS
Alzheimer’s · Parkinson’s · Huntington’s · MS · epilepsy · migraine · depression & psychiatry · stroke · ALS · frontotemporal dementia · rare CNS
Technologies & modalities in play
Small molecules · antisense (ASO) · gene therapy · botulinum toxin · neuromodulation devices · blood-based diagnostics · AI imaging
Key takeaways
Migraine and Alzheimer’s led the week: Ipsen’s Dysport became the first botulinum toxin to hit Phase III across both migraine types, while three separate payers and diagnostics moves pushed Alzheimer’s blood testing toward the mainstream. On the downside, GSK walked away from its Alector neuro-immunology partnership — the latest reminder of how hard CNS remains.
Top stories
Clinical
Dysport becomes the first botulinum toxin with positive Phase III in both episodic and chronic migraine
- Ipsen reported positive topline Phase III results for Dysport (abobotulinumtoxinA) in migraine prevention
- First botulinum toxin to succeed across both episodic and chronic migraine in pivotal trials
- Opens a direct challenge to AbbVie’s Botox, the entrenched leader in chronic-migraine prophylaxis
- A win in episodic migraine would expand the addressable population well beyond Botox’s chronic-only label
- Next: full data presentation and regulatory filing to follow the topline readout
Deal
GSK terminates its Alector neuro-immunology partnership, returning the brain-drug programs
- GSK ended its collaboration with Alector on progranulin-focused neurodegeneration assets
- Rights to the affected brain programs revert to Alector
- Another high-profile CNS pipeline setback, underscoring the risk that keeps neuro dealmaking cautious
- Signals large-pharma discipline on early neuro-immunology after mixed clinical signals
- Next: Alector to outline the path forward for the returned programs
Clinical
atai/Beckley doses last patient in VLS-01 Phase 2b for treatment-resistant depression; Phase 3 planned in MDD
- atai Life Sciences and Beckley Psytech completed dosing in the Phase 2b study of VLS-01 (an oral DMT formulation) in treatment-resistant depression
- The companies plan to advance into Phase 3 in major depressive disorder
- Part of the rapid-acting psychiatry wave challenging conventional antidepressants
- Psychedelic-derived approaches are moving from proof-of-concept toward registrational trials
- Next: Phase 2b readout, then Phase 3 initiation in MDD
Access
Alzheimer’s blood testing goes mainstream: Anthem covers C2N’s PrecivityAD2, as biomarker and payer moves stack up
- Anthem established coverage of C2N Diagnostics’ PrecivityAD2 blood test for Alzheimer’s evaluation
- Alamar Biosciences separately launched the first multiplexed blood-based immunoassay for eMTBR-tau, a key AD biomarker
- Payer coverage is the gate that has throttled Alzheimer’s diagnosis; a major insurer covering a blood test is a real access inflection
- Blood-based testing could dramatically widen the funnel of patients identified for anti-amyloid therapy
- Next: watch whether other national payers follow Anthem’s lead
Designation
Arialys wins FDA Fast Track for ART5803, the first precision therapeutic for anti-NMDA receptor encephalitis
- FDA granted Fast Track to Arialys Therapeutics’ ART5803
- First precision therapeutic candidate in development for anti-NMDA receptor encephalitis, a severe autoimmune neurological disorder
- Addresses a rare condition with no targeted approved therapy
- Fast Track accelerates development and review for a high-unmet-need indication
- Next: continued clinical development under the expedited pathway
Also this week
ClinicalTG Therapeutics initiated a Phase 2 trial of Briumvi (ublituximab) in treatment-resistant schizophrenia, testing a B-cell approach in a new psychiatric setting.
ClinicalPrilenia and Ferrer began the confirmatory PRECISE-HD study of pridopidine in Huntington’s disease, a second shot after prior mixed regulatory signals.
ClinicalAnnovis reached full enrollment in its pivotal Phase 3 of buntanetap for early Alzheimer’s, keeping its oral candidate on a registrational timeline.
ClinicalKenai Therapeutics completed enrollment in the Phase 1b/2a REPLACE trial of RNDP-001, an allogeneic cell therapy for idiopathic Parkinson’s.
ClinicalAxsome initiated the FOCUS-2 Phase 3 of solriamfetol in pediatric ADHD, extending a marketed wake-promoting agent into a large new population.
AccessTheranica’s Nerivio migraine wearable passed coverage for more than half the US insured population, a commercial milestone for prescription digital therapeutics.
ClinicalSerina Therapeutics completed sentinel dosing in a Phase 1b registrational trial of SER-252 for advanced Parkinson’s, advancing its polymer-drug platform.
ClinicalCervoMed completed enrollment in a Phase 2 of neflamapimod for nonfluent primary progressive aphasia, a frontotemporal dementia variant.
In brief
Clinical
Epicrispr completes first-in-human dosing for FSHD – enrollment and dose escalation done in the EPI-321 epigenetic-editing trial.
Penumbra enrolls first patient in FORWARD stroke study – evaluating computer-assisted vacuum thrombectomy for distal ischemic stroke.
Access
Neuspera sacral neuromodulation gains proposed CMS parity – would receive the same 2027 Medicare payment as legacy implantable SNM devices.
Launch
Longeviti launches ClearFit AI brain-ultrasound interface – a new imaging platform aimed at neurological-disorder monitoring.
Partnership
Cumulus Neuroscience partners with Muse (Interaxon) – brings validated at-home sleep EEG into CNS clinical trials.
Oncology + Immunology & Inflammation
Therapy area
Oncology + Immunology & Inflammation
Solid tumors · bladder, prostate, ovarian, pancreatic, colorectal & breast cancer · lymphoma · myeloma · neuroendocrine tumors · autoimmune & inflammatory disease
Technologies & modalities in play
Checkpoint inhibitors · CAR-T · bispecific antibodies · ADCs · radioligands · biosimilars · companion diagnostics · CRISPR platforms
Key takeaways
Regulatory news dominated: Merck’s Keytruda-plus-Padcev bladder-cancer approval was the headline, Genmab’s epcoritamab cleared Europe in follicular lymphoma, and both EMA and FDA put RAS-pathway drugs on expedited tracks. The week wasn’t all green lights — Elevar drew a Complete Response Letter in liver cancer, a reminder the bar stays high.
Oncology
Top stories
Approval
FDA approves Keytruda plus Padcev for muscle-invasive bladder cancer, before and after surgery
- FDA approved Merck’s Keytruda (pembrolizumab), including the QLEX subcutaneous formulation, with Pfizer/Astellas’ Padcev (enfortumab vedotin) for muscle-invasive bladder cancer (MIBC)
- Cleared for use both before (neoadjuvant) and after (adjuvant) surgery
- Extends the Keytruda-Padcev combination, already dominant in metastatic urothelial cancer, into earlier disease
- Earlier-line use expands an already large, well-reimbursed population and deepens Merck’s uro-oncology franchise
- Next: uptake in the perioperative setting and competitive response from rival ADC-IO combinations
Approval
Genmab’s epcoritamab (Tepkinly) approved in Europe for relapsed/refractory follicular lymphoma
- European Commission approved Tepkinly (epcoritamab) with lenalidomide and rituximab for relapsed or refractory follicular lymphoma
- Adds a bispecific-antibody backbone to a standard immunochemotherapy combination
- Strengthens Genmab and AbbVie’s position in the competitive B-cell lymphoma market
- A subcutaneous bispecific offers an off-the-shelf alternative to CAR-T in follicular lymphoma
- Next: EU launch and continued label expansion across lymphoma subtypes
Regulatory
EMA and FDA both fast-track RAS-pathway cancer drugs, led by Revolution Medicines’ daraxonrasib
- EMA is expediting assessment of Revolution Medicines’ daraxonrasib (a RAS(ON) multi-selective inhibitor) under a phased review; EMA separately fast-tracked a metastatic pancreatic cancer medicine
- RAS is one of oncology’s most-pursued and historically undruggable target families
- Pancreatic cancer, a RAS-driven disease with dismal outcomes, is the prime proving ground
- Regulatory acceleration signals confidence in the pan-RAS approach after early clinical activity
- Next: phased-review progress and pivotal data in pancreatic and other RAS-mutant tumors
Clinical
ITM’s Lu-edotreotide beats everolimus in Phase 3 GEP-NETs, published in The Lancet
- ITM reported primary results from the Phase 3 COMPETE trial of Lu-edotreotide (ITM-11) versus everolimus in advanced gastroenteropancreatic neuroendocrine tumors, published in The Lancet
- A radioligand therapy showing superiority over a standard targeted agent
- Reinforces the momentum behind radiopharmaceuticals in neuroendocrine and other tumors
- Peer-reviewed Phase 3 publication strengthens the regulatory and commercial case
- Next: regulatory filings on the strength of the COMPETE data
Also this week
RegulatoryImmunome won FDA acceptance of its NDA for varegacestat in desmoid tumors, moving a rare-oncology candidate toward a possible approval.
RegulatoryA PD-L1x4-1BB bispecific, opamtistomig, received Priority Review in EP-NEC, accelerating a bispecific into a rare neuroendocrine indication.
ApprovalFDA approved Accord BioPharma’s Ennumo (pegfilgrastim-pccg), its second pegfilgrastim biosimilar to Neulasta, deepening supportive-care price competition.
ApprovalNeoGenomics launched an FDA-approved PTEN IHC companion diagnostic for prostate cancer, tying tumor testing to targeted-therapy selection.
RegulatoryElevar received an FDA Complete Response Letter for rivoceranib plus camrelizumab in first-line liver cancer, a setback for the China-origin IO combination.
ClinicalAnixa Biosciences and Moffitt advanced their ovarian-cancer CAR-T to the highest dose level yet, progressing a solid-tumor cell therapy.
In brief
Regulatory
LTZ Therapeutics clears IND for LTZ-232 – targeting advanced metastatic colorectal cancer and other solid tumors.
Coregen gains FDA clearance for CRG-150 – a cell therapy entering Phase 1/2a across multiple solid tumors.
Fate Therapeutics clears IND for FT839 – advancing another off-the-shelf cell-therapy candidate.
Platform
Confluence Genetics launches Cas-CLEAR CRISPR platform – a new gene-editing technology aimed at cancer therapy.
Clinical
Delcath doses first patient with HEPZATO in breast cancer – Phase 2 in liver-dominant metastatic disease.
Immunology & Inflammation
Top stories
Approval
J&J’s Tecvayli-daratumumab combination recommended as potential standard of care in relapsed multiple myeloma
- A CMUH recommendation elevated Johnson & Johnson’s Tecvayli (teclistamab) with daratumumab toward standard-of-care status in relapsed/refractory multiple myeloma
- Pairs a BCMA bispecific with an established anti-CD38 antibody
- Reinforces J&J’s leadership in the crowded, fast-moving myeloma market
- Combination bispecific regimens are reshaping treatment sequencing in myeloma
- Next: guideline adoption and payer positioning across markets
Also this week
ClinicalThe world’s first international patient began treatment with a newly approved solid-tumor CAR-T at a China cancer center, a milestone for cell therapy beyond blood cancers.
RegulatoryVolitionRx released data supporting the prognostic value of its Nu.Q blood-based cancer test, adding to the liquid-biopsy evidence base.
In brief
Clinical
BioLineRx and Hemispherian show preclinical synergy – GLIX1 plus a PARP inhibitor in an ovarian-cancer model.
Regulatory
Vivos receives FDA IDE for RadioGel – clearing a feasibility study of precision radionuclide therapy.
Cardio-Metabolic
Therapy area
Cardio-Metabolic
Obesity · type 2 diabetes · ATTR cardiomyopathy · heart failure · dyslipidemia · structural heart / valves · stroke · Gaucher disease
Technologies & modalities in play
GLP-1 & amylin agonists · antisense (ASO) · gene therapy · cardiac & valve devices · CGM / insulin delivery · AI cardiovascular risk tools
Key takeaways
Obesity kept its grip on the agenda: Kailera and Hengrui posted positive Phase 3 data for an oral small-molecule GLP-1, Ascletis filed two once-monthly amylin INDs, and access widened as Ozempic’s savings program expanded and Health Canada cleared Mounjaro for children. The durability race is on — from oral incretins to next-generation dosing.
Top stories
Clinical
Kailera and Hengrui report positive Phase 3 topline data for oral small-molecule GLP-1 HRS-7535
- Kailera Therapeutics announced positive topline results from two Hengrui Pharma Phase 3 trials of HRS-7535 (KAI-7535), an oral small-molecule GLP-1 receptor agonist
- An oral small molecule, not a peptide — potentially cheaper to make and easier to scale than injectables
- Directly targets the convenience gap that limits injectable GLP-1 adherence and access
- A China-origin asset advancing on the global obesity stage, reinforcing the cross-border trend
- Next: full data and regulatory strategy across major markets
Approval
Health Canada approves Mounjaro (tirzepatide) for children aged 10 and older with type 2 diabetes
- Health Canada cleared Eli Lilly’s Mounjaro (tirzepatide) for pediatric type 2 diabetes in patients 10+
- Extends a leading dual GIP/GLP-1 agonist into a younger population
- Pediatric type 2 diabetes is rising and underserved by modern agents
- Broadens the tirzepatide franchise and lengthens potential treatment duration per patient
- Next: uptake in pediatric practice and similar filings in other geographies
Regulatory
Ascletis files two INDs for once-monthly amylin obesity candidates
- Ascletis submitted two US IND applications for obesity: ASC36, a once-monthly injectable peptide amylin receptor agonist, and ASC3635, a once-monthly co-formulation
- Amylin is the leading next-generation partner mechanism to GLP-1
- Once-monthly dosing would be a major convenience and durability advantage over weekly injectables
- Adds another entrant to the accelerating amylin and combination obesity race
- Next: FDA clearance and first-in-human studies
Clinical
Ionis/AstraZeneca report a CARDIO-TTRansform Phase 3 update for eplontersen in ATTR cardiomyopathy
- An update was issued on the Phase 3 CARDIO-TTRansform trial of eplontersen (an antisense TTR silencer) in transthyretin amyloid cardiomyopathy
- ATTR-CM is one of the highest-stakes cardiovascular markets, with large commercial franchises at play
- An antisense approach competing against stabilizers and other silencers for share
- Cardiac outcomes will determine positioning in a rapidly expanding ATTR field
- Next: full trial results to define eplontersen’s competitive profile
Also this week
AccessNovo Nordisk expanded the Ozempic savings-card program for privately insured patients, sharpening affordability competition in the GLP-1 category.
ClinicalMetaVia completed dose titration in a Phase 1 study of DA-1726 for obesity, advancing another oxyntomodulin-class candidate.
LaunchInsulet launched Omnipod 5 and Omnipod Discover in Spain, expanding access to tubeless automated insulin delivery in Europe.
ClinicalEndogenex reached full enrollment in the RECET study of its device-based procedure for type 2 diabetes, testing a non-pharmacologic approach.
AccessDario signed a major Arizona health insurer via Amwell, extending digital chronic-disease management to hundreds of thousands of lives.
In brief
Clinical
Spur Therapeutics doses first patient in GALILEO-3 for Gaucher – pivotal gene-therapy trial of FLT201 in Gaucher disease type 1.
AtaCor Medical treats first patient in ALARION EV pivotal trial – advancing an extravascular cardiac device.
Nyra Medical enrolls first patient in ENHANCE – early feasibility study of a next-generation mitral-valve repair platform.
Elucid enrolls first patient in AI-PREDICT – an international study defining lesion-level cardiovascular risk with AI.
Approvals, Designations & Launches
Every regulatory action, expedited-review designation and product launch this week, across all therapy areas. The complete reference; the biggest items also appear as full stories in their therapy-area page.
Approvals & decisions
| Date | Agency | Product | Company | Indication | Status |
|---|---|---|---|---|---|
| Jul 10 | FDA | Keytruda + Padcev | Merck / Pfizer-Astellas | Muscle-invasive bladder cancer (peri-op) | Approval |
| Jul | EC | Tepkinly (epcoritamab) | Genmab / AbbVie | R/R follicular lymphoma | Approval |
| Jul 08 | Health Canada | Mounjaro (tirzepatide) | Eli Lilly | Pediatric type 2 diabetes (10+) | Approval |
| Jul 09 | FDA | Ennumo (pegfilgrastim-pccg) | Accord BioPharma | Supportive care (biosimilar) | Approval |
| Jul | FDA | Wilate (expanded) | Octapharma | von Willebrand disease, children <6 | Approval |
| Jul 09 | FDA | PTEN IHC companion Dx | NeoGenomics | Prostate cancer testing | Approval |
| Jul 08 | FDA | CliniComp PACS / mIMPS | CliniComp | Diagnostic imaging + AI | Clearance |
| Jul 10 | FDA | Rivoceranib + camrelizumab | Elevar | First-line liver cancer | CRL (rejected) |
Designations & expedited review
| Date | Agency | Designation | Company | Asset | Indication |
|---|---|---|---|---|---|
| Jul 09 | FDA | Fast Track | Arialys | ART5803 | Anti-NMDA receptor encephalitis |
| Jul 07 | EMA | Phased / expedited review | Revolution Medicines | Daraxonrasib | RAS-mutant cancers |
| Jul | EMA | Fast-track review | (undisclosed) | – | Metastatic pancreatic cancer |
| Jul | FDA | Priority Review | (sponsor) | Opamtistomig (PD-L1x4-1BB) | EP-NEC |
| Jul 08 | FDA | NDA acceptance | Immunome | Varegacestat | Desmoid tumors |
Launches
| Date | Company | Product | Category |
|---|---|---|---|
| Jul 07 | Alamar Biosciences | eMTBR-tau blood immunoassay | Alzheimer’s biomarker testing |
| Jul 06 | Insulet | Omnipod 5 / Omnipod Discover (Spain) | Automated insulin delivery |
| Jun 25 | Longeviti | ClearFit AI (brain ultrasound) | Neurological monitoring |
| Jul 09 | Confluence Genetics | Cas-CLEAR CRISPR platform | Cancer gene editing |
Synopulse · The Pulse – the weekly cross-therapy briefing. One hub, four therapy pages, every regulatory action in one place. The Hub indexes the week; each therapy page carries the depth. Skim the titles, open what matters.